
Richard Cook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3072569/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The number needed to treat: a clinically useful measure of treatment effect. BMJ: British Medical Journal, 1995, 310, 452-454.	2.4	1,615
2	Methods for assessing responsiveness. Journal of Clinical Epidemiology, 2000, 53, 459-468.	2.4	1,224
3	Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients. Annals of Internal Medicine, 1998, 129, 433.	2.0	770
4	Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 2007, 110, 1860-1867.	2.0	559
5	Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. European Respiratory Journal, 2006, 27, 483-494.	3.1	548
6	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute, 2005, 97, 59-69.	3.0	522
7	Canadian Hemodialysis Morbidity Study. American Journal of Kidney Diseases, 1992, 19, 214-234.	2.1	515
8	Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. Journal of Clinical Oncology, 2005, 23, 4925-4935.	0.8	493
9	Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. Annals of Internal Medicine, 2007, 146, 25.	2.0	477
10	Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 2918-2925.	0.8	430
11	Monitoring surgical performance using risk-adjusted cumulative sum charts. Biostatistics, 2000, 1, 441-452.	0.9	371
12	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	302
13	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	13.9	278
14	Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106, 3791-3796.	0.6	271
15	Interobserver Variation in Interpreting Chest Radiographs for the Diagnosis of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 85-90.	2.5	245
16	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer, 2008, 113, 193-201.	2.0	243
17	Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Critical Care Medicine, 1999, 27, 2812-2817.	0.4	238
18	Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care and Research, 2011, 63, 1729-1735.	1.5	214

#	Article	IF	CITATIONS
19	Stress ulcer prophylaxis in the critically III: A meta-analysis. American Journal of Medicine, 1991, 91, 519-527.	0.6	213
20	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	15.2	206
21	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 915-923.	2.9	197
22	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Annals of the Rheumatic Diseases, 2011, 70, 2152-2154.	0.5	183
23	The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood, 2013, 122, 1946-1953.	0.6	168
24	Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2014, 311, 2191.	3.8	167
25	MARGINAL ANALYSIS OF RECURRENT EVENTS AND A TERMINATING EVENT. , 1997, 16, 911-924.		163
26	Studies of the immune response in heparin-induced thrombocytopenia. Blood, 2009, 113, 4963-4969.	0.6	157
27	Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2006, 12, 3361-3367.	3.2	156
28	Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporosis International, 2003, 14, 677-682.	1.3	155
29	Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity. Journal of Thoracic Oncology, 2008, 3, 228-236.	0.5	155
30	Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castrationâ€resistant nonmetastatic prostate cancer. Cancer, 2011, 117, 2077-2085.	2.0	152
31	A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood, 2009, 113, 1564-1573.	0.6	150
32	A 1-Year Community-Based Health Economic Study of Ciprofloxacin vs Usual Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. Chest, 1998, 113, 131-141.	0.4	147
33	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology, 2010, 49, 1399-1405.	0.9	142
34	Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. Journal of Thrombosis and Haemostasis, 2009, 7, 676-684.	1.9	141
35	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 813-817.	0.5	138
36	Does Cox analysis of a randomized survival study yield a causal treatment effect?. Lifetime Data Analysis, 2015, 21, 579-593.	0.4	136

#	Article	IF	CITATIONS
37	Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. Journal of Rheumatology, 1997, 24, 511-7.	1.0	133
38	Radiological assessment in psoriatic arthritis. Rheumatology, 1998, 37, 760-765.	0.9	124
39	Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study. Lancet, The, 2001, 358, 1941-1945.	6.3	120
40	Analysis of repeated events. Statistical Methods in Medical Research, 2002, 11, 141-166.	0.7	117
41	Multiple organ dysfunction: Baseline and serial component scores. Critical Care Medicine, 2001, 29, 2046-2050.	0.4	116
42	Prediction of falls using a risk assessment tool in the acute care setting. BMC Medicine, 2004, 2, 1.	2.3	115
43	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care and Research, 2011, 63, 1091-1097.	1.5	112
44	When should an effective treatment be used?. Journal of Clinical Epidemiology, 2001, 54, 253-262.	2.4	111
45	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	0.6	111
46	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care and Research, 2010, 62, 970-976.	1.5	110
47	The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica, 2006, 91, 1530-7.	1.7	110
48	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	3.4	108
49	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis and Rheumatism, 2009, 61, 1235-1242.	6.7	104
50	Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal, 2010, 159, 737-743.e1.	1.2	101
51	Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 809-815.	1.0	94
52	Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. Journal of Rheumatology, 2000, 27, 1892-5.	1.0	94
53	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. Arthritis and Rheumatology, 2017, 69, 622-629.	2.9	93
54	Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity. Oncologist, 2007, 12, 1035-1043.	1.9	92

#	Article	IF	CITATIONS
55	Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 2010, 24, 1043-1049.	3.3	91
56	Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, S10-S18.	0.6	90
57	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. Rheumatology, 2020, 59, 1340-1346.	0.9	88
58	Relative Change in Diurnal Mean Ocular Perfusion Pressure: A Risk Factor for the Diagnosis of Primary Open-Angle Glaucoma. , 2005, 46, 561.		86
59	Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 2003, 43, 742-752.	0.8	85
60	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1680-1686.	0.5	85
61	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	2.0	84
62	Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporosis International, 2003, 14, 913-917.	1.3	81
63	Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care and Research, 2011, 63, 619-622.	1.5	81
64	Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. Journal of Critical Care, 2005, 20, 357-363.	1.0	76
65	Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. Clinical Cancer Research, 2012, 18, 6348-6355.	3.2	76
66	The association between smoking and the development of psoriatic arthritis among psoriasis patients. Annals of the Rheumatic Diseases, 2012, 71, 219-224.	0.5	75
67	International spondyloarthritis interobserver reliability exercisethe INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	1.0	74
68	Clinical and radiological damage in psoriatic arthritis. Annals of the Rheumatic Diseases, 2006, 65, 478-481.	0.5	73
69	HLA markers and progression in psoriatic arthritis. Journal of Rheumatology, 1998, 25, 730-3.	1.0	72
70	Robust Tests for Treatment Comparisons Based on Recurrent Event Responses. Biometrics, 1996, 52, 557.	0.8	71
71	Agreement between Alternative Classifications of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 490-493.	2.5	71
72	Marginal Analysis of Incomplete Longitudinal Binary Data: A Cautionary Note on LOCF Imputation. Biometrics, 2004, 60, 820-828.	0.8	71

#	Article	IF	CITATIONS
73	Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin. Anesthesia and Analgesia, 2006, 102, 731-737.	1.1	71
74	Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology, 2010, 49, 1367-1373.	0.9	70
75	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1830-1835.	0.5	70
76	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Populationâ€Based Study. Arthritis Care and Research, 2019, 71, 1084-1091.	1.5	68
77	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis, 2014, 112, 692-699.	1.8	67
78	Genome-wide analysis of disease progression in age-related macular degeneration. Human Molecular Genetics, 2018, 27, 929-940.	1.4	67
79	Monitoring the evolutionary process of quality: Risk-adjusted charting to track outcomes in intensive care. Critical Care Medicine, 2003, 31, 1676-1682.	0.4	66
80	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Annals of the Rheumatic Diseases, 2010, 69, 2160-2164.	0.5	66
81	Marginal Methods for Incomplete Longitudinal Data Arising in Clusters. Journal of the American Statistical Association, 2002, 97, 1071-1080.	1.8	63
82	Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients. Arthritis Care and Research, 2015, 67, 264-272.	1.5	63
83	Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer. Urology, 2007, 70, 315-319.	0.5	62
84	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779.	1.1	62
85	Risk Factors for Hip Fracture in Older Home Care Clients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 403-410.	1.7	61
86	The effect of blood storage duration on inâ€hospital mortality: a randomized controlled pilot feasibility trial. Transfusion, 2012, 52, 1203-1212.	0.8	61
87	The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. Journal of Rheumatology, 2004, 31, 1126-31.	1.0	60
88	Whole stimulated salivary flow: Correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sj¶gren's syndrome but not patients with sicca. Arthritis and Rheumatism, 2011, 63, 2014-2020.	6.7	58
89	Remission in psoriatic arthritis. Journal of Rheumatology, 2001, 28, 1045-8.	1.0	58
90	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. Lancet Haematology,the, 2016, 3, e246-e254.	2.2	57

#	Article	IF	CITATIONS
91	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Research and Therapy, 2017, 19, 189.	1.6	57
92	International spondyloarthritis interobserver reliability exercisethe INSPIRE study: I. Assessment of spinal measures. Journal of Rheumatology, 2007, 34, 1733-9.	1.0	57
93	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 134-45.	1.8	55
94	Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone. Journal of the National Cancer Institute, 2001, 93, 534-538.	3.0	54
95	Monitoring paired binary surgical outcomes using cumulative sum charts. , 1999, 18, 69-86.		53
96	A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion, 2007, 48, 071003012013009-???.	0.8	53
97	Robust Estimation of Mean Functions and Treatment Effects for Recurrent Events Under Event-Dependent Censoring and Termination: Application to Skeletal Complications in Cancer Metastatic to Bone. Journal of the American Statistical Association, 2009, 104, 60-75.	1.8	53
98	Antiâ€PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of nonâ€drug risk factors and evidence for a stoichiometryâ€based model of immunization. Journal of Thrombosis and Haemostasis, 2010, 8, 504-512.	1.9	51
99	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion, 2019, 59, 482-491.	0.8	51
100	Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis — GRAPPA Ultrasound Working Group. Journal of Rheumatology, 2019, 46, 384-390.	1.0	50
101	Multistate Models for the Analysis of Life History Data. , 0, , .		50
102	Using inverse-weighting in cost-effectiveness analysis with censored data. Statistical Methods in Medical Research, 2002, 11, 539-551.	0.7	49
103	Rehabilitation in Home Care Is Associated With Functional Improvement and Preferred Discharge. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1038-1047.	0.5	49
104	Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. Arthritis and Rheumatology, 2018, 70, 408-416.	2.9	49
105	Weighted Generalized Estimating Functions for Longitudinal Response and Covariate Data That Are Missing at Random. Journal of the American Statistical Association, 2010, 105, 336-353.	1.8	48
106	Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis. Journal of Rheumatology, 2013, 40, 866-871.	1.0	48
107	The design and analysis of randomized trials with recurrent events. Statistics in Medicine, 1995, 14, 2081-2098.	0.8	46
108	A generalized mover-stayer model for panel data. Biostatistics, 2002, 3, 407-420.	0.9	46

#	Article	IF	CITATIONS
109	Zoledronic acid use in cancer patients. Cancer, 2011, 117, 11-23.	2.0	46
110	Bivariate Analysis of Age-Related Macular Degeneration Progression Using Genetic Risk Scores. Genetics, 2017, 206, 119-133.	1.2	46
111	Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion, 2004, 44, 1135-1142.	0.8	45
112	A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, 2006, 46, 903-911.	0.8	45
113	Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis. Arthritis Care and Research, 2015, 67, 842-847.	1.5	45
114	Incidence of Clinically Important Bleeding in Mechanically Ventilated Patients. Journal of Intensive Care Medicine, 1991, 6, 167-174.	1.3	44
115	Reliability of electrocardiogram interpretation in critically ill patients*. Critical Care Medicine, 2006, 34, 1338-1343.	0.4	44
116	Incremental net benefit in randomized clinical trials with quality-adjusted survival. Statistics in Medicine, 2003, 22, 353-362.	0.8	43
117	Conditional inference for subject-specific and marginal agreement: Two families of agreement measures. Canadian Journal of Statistics, 1995, 23, 333-344.	0.6	39
118	Statistical methods for multivariate interval-censored recurrent events. Statistics in Medicine, 2005, 24, 671-691.	0.8	39
119	Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer, 2009, 9, 272.	1.1	39
120	Effect of Pregnancy on Ankylosing Spondylitis: A Case-Control Study. Journal of Rheumatology, 2011, 38, 2442-2444.	1.0	39
121	Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood, 2015, 126, 486-493.	0.6	39
122	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. Journal of Rheumatology, 2017, 44, 286-291.	1.0	39
123	A Conditional Markov Model for Clustered Progressive Multistate Processes under Incomplete Observation. Biometrics, 2004, 60, 436-443.	0.8	38
124	Interim Monitoring of Longitudinal Comparative Studies with Recurrent Event Responses. Biometrics, 1996, 52, 1311.	0.8	35
125	Regression analysis of multivariate panel count data. Biostatistics, 2007, 9, 234-248.	0.9	35
126	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	1.0	34

#	Article	IF	CITATIONS
127	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	2.2	34
128	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 796-801.	0.5	34
129	Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics, 2004, 5, 129-143.	0.9	33
130	A robust pairwise likelihood method for incomplete longitudinal binary data arising in clusters. Canadian Journal of Statistics, 2011, 39, 34-51.	0.6	33
131	A Revisit of the Criteria To Define Remission in Patients with Idiopathic Thrombocytopenia Undergoing Splenectomy Blood, 2005, 106, 3020-3020.	0.6	33
132	Anterior Optic Nerve Capillary Blood Flow Response to Diurnal Variation of Mean Ocular Perfusion Pressure in Early Untreated Primary Open-Angle Glaucoma. , 2005, 46, 4581.		31
133	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care and Research, 2011, 63, 1440-1447.	1.5	30
134	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. Journal of Rheumatology, 2016, 43, 362-366.	1.0	30
135	Time and predictors of response to tumour necrosis factor-Â blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology, 2010, 49, 1361-1366.	0.9	29
136	Analysis of timeâ€ŧoâ€event for observational studies: Guidance to the use of intensity models. Statistics in Medicine, 2021, 40, 185-211.	0.8	29
137	A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. European Journal of Haematology, 2013, 90, 121-126.	1.1	28
138	Estimation of Operating Characteristics for Dependent Diagnostic Tests Based on Latent Markov Models. Biometrics, 2000, 56, 1109-1117.	0.8	27
139	Analysis of interval ensored disease progression data via multiâ€state models under a nonignorable inspection process. Statistics in Medicine, 2010, 29, 1175-1189.	0.8	27
140	Safe abortion: WHO technical and policy guidance. International Journal of Gynecology and Obstetrics, 2004, 86, 79-84.	1.0	26
141	Survival-Adjusted Multiple-Event Analysis for the Evaluation of Treatment Effects of Zoledronic Acid in Patients with Bone Metastases from Solid Tumors. Supportive Cancer Therapy, 2005, 2, 234-240.	0.3	26
142	A Multistate Model for Bivariate Interval ensored Failure Time Data. Biometrics, 2008, 64, 1100-1109.	0.8	26
143	Iron-containing micronutrient powder provided to children with moderate-to-severe malnutrition increases hemoglobin concentrations but not the risk of infectious morbidity: a randomized, double-blind, placebo-controlled, noninferiority safety trial. American Journal of Clinical Nutrition, 2011. 94. 585-593.	2.2	26
144	Penalized regression for interval ensored times of disease progression: Selection of HLA markers in psoriatic arthritis. Biometrics, 2015, 71, 782-791.	0.8	26

#	Article	IF	CITATIONS
145	A Mixed Model for Two-State Markov Processes Under Panel Observation. Biometrics, 1999, 55, 915-920.	0.8	25
146	A copulaâ€based mixed Poisson model for bivariate recurrent events under eventâ€dependent censoring. Statistics in Medicine, 2010, 29, 694-707.	0.8	25
147	Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 1417-1422.	1.5	25
148	Statistical Issues in Modeling Chronic Disease in Cohort Studies. Statistics in Biosciences, 2014, 6, 127-161.	0.6	25
149	Exploratory studies on the age of transfused blood and inâ€hospital mortality in patients with cardiovascular diagnoses. Transfusion, 2015, 55, 364-372.	0.8	25
150	Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 346-353.	1.4	24
151	International developments in abortion laws: 1977-88 American Journal of Public Health, 1988, 78, 1305-1311.	1.5	23
152	Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration. Oncologist, 2012, 17, 645-652.	1.9	23
153	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. Seminars in Arthritis and Rheumatism, 2020, 50, 571-575.	1.6	23
154	DISCUSSION OF PAPER BY WEI AND GLIDDEN. Statistics in Medicine, 1997, 16, 841-851.	0.8	22
155	Twoâ€stage design of clinical trials involving recurrent events. Statistics in Medicine, 2009, 28, 2617-2638.	0.8	22
156	Adaptive sampling in twoâ€phase designs: a biomarker study for progression in arthritis. Statistics in Medicine, 2015, 34, 2899-2912.	0.8	22
157	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. Arthritis and Rheumatology, 2019, 71, 1651-1659.	2.9	22
158	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2022, 74, 1430-1434.	1.5	22
159	Interim monitoring of bivariate responses using repeated confidence intervals. Contemporary Clinical Trials, 1994, 15, 187-200.	2.0	21
160	Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis. Biostatistics, 2003, 4, 479-494.	0.9	21
161	Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion, 2005, 45, 896-903.	0.8	21
162	Bias in progressionâ€free survival analysis due to intermittent assessment of progression. Statistics in Medicine, 2015, 34, 3181-3193.	0.8	21

#	Article	IF	CITATIONS
163	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	0.7	21
164	Effects of prenatal alcohol exposure on cognitive and behavioral development: Findings from a hierarchical metaâ€analysis of data from six prospective longitudinal U.S. cohorts. Alcoholism: Clinical and Experimental Research, 2021, 45, 2040-2058.	1.4	21
165	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 01-12.	1.8	20
166	Group O <scp>RBC</scp> s: where is universal donor blood being used. Vox Sanguinis, 2017, 112, 336-342.	0.7	20
167	Two-state mixed renewal processes for chronic disease. , 1999, 18, 175-188.		19
168	Analysis of Interval-Censored Data from Clustered Multistate Processes: Application to Joint Damage in Psoriatic Arthritis. Journal of the Royal Statistical Society Series C: Applied Statistics, 2008, 57, 553-566.	0.5	19
169	Selection effects in randomized trials with count data. Statistics in Medicine, 2002, 21, 515-531.	0.8	18
170	Exposure to <scp>ABO</scp> â€nonidentical blood associated with increased inâ€hospital mortality in patients with group <scp>A</scp> blood. Transfusion, 2016, 56, 550-557.	0.8	18
171	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48, 638-643.	1.6	18
172	Liver Abnormalities in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 847-853.	1.0	18
173	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. Journal of Rheumatology, 2022, 49, 523-530.	1.0	18
174	A Logistic-Bivariate Normal Model for Overdispersed Two-State Markov Processes. Biometrics, 1997, 53, 358.	0.8	17
175	Modeling two-state disease processes with random effects. , 1997, 3, 315-335.		17
176	Robust inference for bivariate point processes. Canadian Journal of Statistics, 1999, 27, 509-524.	0.6	17
177	Composite outcomes in clinical trials: what are they and when should they be used?. Transfusion, 2011, 51, 11-13.	0.8	17
178	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Seminars in Arthritis and Rheumatism, 2021, 51, 464-468.	1.6	17
179	The analysis of multivariate recurrent events with partially missing event types. Lifetime Data Analysis, 2009, 15, 41-58.	0.4	16
180	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	1.0	16

#	Article	IF	CITATIONS
181	Misspecification of Cox regression models with composite endpoints. Statistics in Medicine, 2012, 31, 3545-3562.	0.8	16
182	Responseâ€dependent twoâ€phase sampling designs for biomarker studies. Canadian Journal of Statistics, 2014, 42, 268-284.	0.6	16
183	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e640-e648.	2.2	16
184	Transition Models for Multivariate Longitudinal Binary Data. Journal of the American Statistical Association, 2007, 102, 211-223.	1.8	15
185	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. Journal of Thrombosis and Haemostasis, 2012, 10, 148-150.	1.9	15
186	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews, 2016, 30, 25-29.	0.9	15
187	Adjusted Score Tests of Homogeneity for Poisson Processes. Journal of the American Statistical Association, 1999, 94, 308-319.	1.8	14
188	Multistate Analysis of Skeletal Events in Patients with Bone Metastases. Clinical Cancer Research, 2006, 12, 6264s-6269s.	3.2	14
189	Clinical trials evaluating pathogenâ€reduced platelet products: methodologic issues and recommendations. Transfusion, 2013, 53, 1843-1855.	0.8	14
190	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1700-1705.	1.5	14
191	The Association Between <scp>HLA</scp> Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 756-762.	2.9	14
192	Copula-based score test for bivariate time-to-event data, with application to a genetic study of AMD progression. Lifetime Data Analysis, 2019, 25, 546-568.	0.4	14
193	Declining levels of serum chemokine (Câ€X motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*. British Journal of Dermatology, 2020, 183, 920-927.	1.4	14
194	A meta-analysis of case-control and cohort studies with interval-censored exposure data: application to chorionic villus sampling. Biostatistics, 2000, 1, 203-217.	0.9	13
195	A Coxâ€Aalen Model for Intervalâ€censored Data. Scandinavian Journal of Statistics, 2015, 42, 414-426.	0.9	13
196	Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics, 1994, 50, 1146-52.	0.8	13
197	Implications of Model Misspecification in Robust Tests for Recurrent Events. Lifetime Data Analysis, 2006, 12, 69-95.	0.4	12
198	Inverse Probability of Censoring Weighted Estimates of Kendall's Ï,, for Gap Time Analyses. Biometrics, 2010, 66, 1145-1152.	0.8	12

#	Article	IF	CITATIONS
199	Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial. BMJ Open, 2012, 2, e001080.	0.8	12
200	Gene-Based Association Analysis for Censored Traits Via Fixed Effect Functional Regressions. Genetic Epidemiology, 2016, 40, 133-143.	0.6	12
201	Sieve estimation in a Markov illness-death process under dual censoring. Biostatistics, 2016, 17, 350-363.	0.9	12
202	Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion, 2018, 58, 2841-2860.	0.8	12
203	Identifying patterns of alcohol use among secondary school students in Canada: A multilevel latent class analysis. Addictive Behaviors, 2020, 100, 106120.	1.7	12
204	Second-order estimating equations for the analysis of clustered current status data. Biostatistics, 2009, 10, 756-772.	0.9	11
205	The Impact of Retardance Pattern Variability on Nerve Fiber Layer Measurements over Time Using GDx with Variable and Enhanced Corneal Compensation. , 2011, 52, 4516.		11
206	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. Journal of Rheumatology, 2016, 43, 1844-1851.	1.0	11
207	Independence conditions and the analysis of life history studies with intermittent observation. Biostatistics, 2021, 22, 455-481.	0.9	11
208	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	0.8	11
209	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2021, 80, 1429-1435.	0.5	11
210	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 547-552.	1.6	11
211	Regression modeling with recurrent events and time-dependent interval-censored marker data. Lifetime Data Analysis, 2003, 9, 275-291.	0.4	10
212	A 6-Mo Home-Based Exercise Program May Slow Vertebral Height Loss. Journal of Clinical Densitometry, 2003, 6, 391-400.	0.5	10
213	Robust Tests for Treatment Effects Based on Censored Recurrent Event Data Observed over Multiple Periods. Biometrics, 2005, 61, 692-701.	0.8	10
214	Likelihood analysis of joint marginal and conditional models for longitudinal categorical data. Canadian Journal of Statistics, 2009, 37, 182-205.	0.6	10
215	CANadian Network and Centre for Trials INternationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. Canadian Journal of Cardiology, 2010, 26, 353-358.	0.8	10
216	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. Seminars in Arthritis and Rheumatism, 2021, 51, 144-149.	1.6	10

#	Article	IF	CITATIONS
217	Adaptive responseâ€dependent twoâ€phase designs: Some results on robustness and efficiency. Statistics in Medicine, 0, , .	0.8	10
218	Synthesis of Evidence from Epidemiological Studies with Interval-Censored Exposure Due to Grouping. Biometrics, 2001, 57, 671-680.	0.8	9
219	Analysis of a nonsusceptible fraction with current status data. Statistics in Medicine, 2008, 27, 2715-2730.	0.8	9
220	The Association Between Diurnal Variation of Optic Nerve Head Topography and Intraocular Pressure and Ocular Perfusion Pressure in Untreated Primary Open-angle Glaucoma. Journal of Glaucoma, 2011, 20, 44-50.	0.8	9
221	Clinical Correlates of Urolithiasis in Ankylosing Spondylitis. Journal of Rheumatology, 2011, 38, 1953-1956.	1.0	9
222	Composite likelihood for joint analysis of multiple multistate processes via copulas. Biostatistics, 2014, 15, 690-705.	0.9	9
223	Transfusionâ€related alloimmunization in children: epidemiology and effects of chemotherapy. Vox Sanguinis, 2016, 111, 299-307.	0.7	9
224	Augmented composite likelihood for copula modeling in family studies under biased sampling. Biostatistics, 2016, 17, 437-452.	0.9	9
225	Dependence modeling for multiâ€ŧype recurrent events via copulas. Statistics in Medicine, 2019, 38, 4066-4082.	0.8	9
226	The Pattern of Musculoskeletal Complaints in Patients With Suspected Psoriatic Arthritis and Their Correlation With Physical Examination and Ultrasound. Journal of Rheumatology, 2021, 48, 214-221.	1.0	9
227	Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study. Arthritis Care and Research, 2022, 74, 1244-1253.	1.5	9
228	Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics, 1996, 52, 1311-23.	0.8	9
229	Information in the sample covariate distribution in prevalent cohorts. Statistics in Medicine, 2011, 30, 1397-1409.	0.8	8
230	Assessing the accuracy of predictive models with interval-censored data. Biostatistics, 2022, 23, 18-33.	0.9	8
231	Understanding COVIDâ€19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Populationâ€based analysis of SARSâ€CoVâ€2 Testing. Arthritis Care and Research, 2021, , .	1.5	8
232	Progressive multi-state models for informatively incomplete longitudinal data. Journal of Statistical Planning and Inference, 2011, 141, 80-93.	0.4	7
233	Testing for Monotone Trend in Recurrent Event Processes. Technometrics, 2012, 54, 147-158.	1.3	7
234	A dynamic Mover–Stayer model for recurrent event processes subject to resolution. Lifetime Data Analysis, 2014, 20, 404-423.	0.4	7

#	Article	IF	CITATIONS
235	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. Journal of Rheumatology, 2016, 43, 1057-1062.	1.0	7
236	A new perspective on loss to followâ€up in failure time and life history studies. Statistics in Medicine, 2019, 38, 4583-4610.	0.8	7
237	Remission in psoriatic arthritis: Definition and predictors. Seminars in Arthritis and Rheumatism, 2020, 50, 1494-1499.	1.6	7
238	Propensity Score Analysis for a Semi-Continuous Exposure Variable: A Study of Gestational Alcohol Exposure and Childhood Cognition. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 1390-1413.	0.6	7
239	Identifying trajectories of alcohol use in a sample of secondary school students in Ontario and Alberta: longitudinal evidence from the COMPASS study. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2019, 39, 244-253.	0.8	7
240	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, 2021, , .	2.5	7
241	Design Considerations in Crossover Trials with a Single Interim Analysis and Serial Patient Entry. Biometrics, 1996, 52, 732.	0.8	6
242	Clinical Endpoints for Assessing Bisphosphonate Efficacy in the Prevention of Skeletal Complications of Bone Metastases. European Urology Supplements, 2004, 3, 34-39.	0.1	6
243	Non-inferiority trial design for recurrent events. Statistics in Medicine, 2007, 26, 4563-4577.	0.8	6
244	The role of noninferiority designs in clinical research. Transfusion, 2008, 48, 1050-1052.	0.8	6
245	Causal inference in nonrandomized studies via propensity score methods. Transfusion, 2011, 51, 2536-2539.	0.8	6
246	A copula model for marked point processes. Lifetime Data Analysis, 2013, 19, 463-489.	0.4	6
247	Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. Dermatology, 2013, 226, 19-27.	0.9	6
248	Sample size and robust marginal methods for clusterâ€randomized trials with censored event times. Statistics in Medicine, 2015, 34, 901-923.	0.8	6
249	Statistical methods for incomplete data: Some results on model misspecification. Statistical Methods in Medical Research, 2017, 26, 248-267.	0.7	6
250	The effect of omitted covariates in marginal and partially conditional recurrent event analyses. Lifetime Data Analysis, 2019, 25, 280-300.	0.4	6
251	Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models. Computer Methods and Programs in Biomedicine, 2019, 177, 269-275.	2.6	6
252	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood, 2013, 122, 3651-3651.	0.6	6

#	Article	IF	CITATIONS
253	Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. Journal of Gastrointestinal Oncology, 2015, 6, 274-9.	0.6	6
254	Design of cancer trials based on progressionâ€free survival with intermittent assessment. Statistics in Medicine, 2018, 37, 1947-1959.	0.8	5
255	Linear mixed models for association analysis of quantitative traits with nextâ€generation sequencing data. Genetic Epidemiology, 2019, 43, 189-206.	0.6	5
256	The impact of an alcohol policy change on developmental trajectories of youth alcohol use: examination of a natural experiment in Canada. Canadian Journal of Public Health, 2021, 112, 210-218.	1.1	5
257	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. Journal of Rheumatology, 2021, 48, 1824-1829.	1.0	5
258	Response-Dependent Sampling with Clustered and Longitudinal Data. Lecture Notes in Statistics, 2013, , 157-181.	0.1	5
259	A conditional frailty model for bivariate interval-truncated failure time data: an application to a study on siblings diagnosed with schizophrenia. Journal of Medical Statistics and Informatics, 2016, 4, 1.	0.8	5
260	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	2.9	5
261	Incorporating Surrogate Endpoints into Group Sequential Trials. Biometrical Journal, 1996, 38, 119-130.	0.6	4
262	The Utility of Mixed-Form Likelihoods. Biometrics, 1999, 55, 284-288.	0.8	4
263	Sequential Testing with Recurrent Events over Multiple Treatment Periods. Statistics in Biosciences, 2010, 2, 137-153.	0.6	4
264	The analysis of treatment effects for recurring episodic conditions. Statistics in Medicine, 2010, 29, 1539-1558.	0.8	4
265	Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group. Trials, 2011, 12, 48.	0.7	4
266	The Design of Intervention Trials Involving Recurrent and Terminal Events. Statistics in Biosciences, 2013, 5, 261-285.	0.6	4
267	Analysis of interval ensored recurrent event processes subject to resolution. Biometrical Journal, 2015, 57, 725-742.	0.6	4
268	Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus. Journal of Clinical Rheumatology, 2017, 23, 301-307.	0.5	4
269	Variable selection and prediction in biased samples with censored outcomes. Lifetime Data Analysis, 2018, 24, 72-93.	0.4	4
270	Geneâ€based association analysis of survival traits via functional regressionâ€based mixed effect cox models for related samples. Genetic Epidemiology, 2019, 43, 952-965.	0.6	4

#	Article	IF	CITATIONS
271	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The) Tj ETQq1 1	0.784314 1.8	rgBT /Overlo
272	Determining the long-term health burden and risk of sequelae for 14 foodborne infections in British Columbia, Canada: protocol for a retrospective population-based cohort study. BMJ Open, 2020, 10, e036560.	0.8	4
273	Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic. Arthritis Care and Research, 2022, 74, 1254-1262.	1.5	4
274	Adjusted Score Tests of Homogeneity for Poisson Processes. Journal of the American Statistical Association, 1999, 94, 308.	1.8	4
275	Number Needed to Treat for Recurrent Events. Journal of Biometrics & Biostatistics, 2013, 04, .	4.0	4
276	Coupled error spending functions for parallel bivariate sequential tests. Biometrics, 1996, 52, 442-50.	0.8	4
277	Robust tests for treatment comparisons based on recurrent event responses. Biometrics, 1996, 52, 557-71.	0.8	4
278	Changing Pattern of Sputum Cell Counts During Successive Exacerbations of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 628-35.	0.7	4
279	Classical Regression and Predictive Modeling. World Neurosurgery, 2022, 161, 251-264.	0.7	4
280	Marginal Analysis of Point Processes with Competing Risks. Handbook of Statistics, 2003, 23, 349-361.	0.4	3
281	Robust Estimation of State Occupancy Probabilities for Interval-Censored Multistate Data: An Application Involving Spondylitis in Psoriatic Arthritis. Communications in Statistics - Theory and Methods, 2009, 38, 3307-3325.	0.6	3
282	Goodnessâ€ofâ€fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals. Statistics in Medicine, 2017, 36, 362-377.	0.8	3
283	Understanding nonâ€inferiority trials and tests for the nonâ€statistician: when to use them and how to interpret them. Transfusion, 2017, 57, 240-243.	0.8	3
284	Second-Order Estimating Equations for Clustered Current Status Data from Family Studies Using Response-Dependent Sampling. Statistics in Biosciences, 2018, 10, 160-183.	0.6	3
285	Tracing studies in cohorts with attrition: Selection models for efficient sampling. Statistics in Medicine, 2018, 37, 2354-2366.	0.8	3
286	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. Clinical Rheumatology, 2019, 38, 1063-1066.	1.0	3
287	Testing the heritability and parentâ€ofâ€origin hypotheses for ages at onset of psoriatic arthritis under biased sampling. Biometrics, 2020, 76, 293-303.	0.8	3
288	A Mixture Model for Bivariate Interval-Censored Failure Times with Dependent Susceptibility. Statistics in Biosciences, 2020, 12, 37-62.	0.6	3

#	Article	IF	CITATIONS
289	Gene-Based Association Testing of Dichotomous Traits With Generalized Functional Linear Mixed Models Using Extended Pedigrees: Applications to Age-Related Macular Degeneration. Journal of the American Statistical Association, 2021, 116, 531-545.	1.8	3
290	Measurement Error for Age of Onset in Prevalent Cohort Studies. Applied Mathematics, 2014, 05, 1672-1683.	0.1	3
291	A logistic-bivariate normal model for overdispersed two-state Markov processes. Biometrics, 1997, 53, 358-64.	0.8	3
292	Multistate models for the natural history of cancer progression. British Journal of Cancer, 2022, 127, 1279-1288.	2.9	3
293	SEMIPARAMETRIC CONFIDENCE INTERVALS BASED ON ESTIMATING FUNCTIONS. Communications in Statistics - Theory and Methods, 2002, 31, 1701-1708.	0.6	2
294	P61. Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC). Cancer Treatment Reviews, 2008, 34, 28-29.	3.4	2
295	FALL-RELATED HIP FRACTURES. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1199-1199.	1.7	2
296	A Bivariate Mover–Stayer Model for Interval-Censored Recurrent Event Data: Application to Joint Damage in Rheumatology. Communications in Statistics - Theory and Methods, 2009, 38, 3389-3405.	0.6	2
297	Estimating functions for evaluating treatment effects in clusterâ€randomized longitudinal studies in the presence of dropâ€out and nonâ€compliance. Canadian Journal of Statistics, 2010, 38, 232-255.	0.6	2
298	Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. Biometrics, 2010, 66, 415-425.	0.8	2
299	Marginal methods for clustered longitudinal binary data with incomplete covariates. Journal of Statistical Planning and Inference, 2012, 142, 2819-2831.	0.4	2
300	Regression with incomplete covariates and leftâ€ŧruncated timeâ€ŧoâ€event data. Statistics in Medicine, 2013, 32, 1004-1015.	0.8	2
301	Authors' redress on â€~Robustness of methods for blinded sample size reâ€estimation with overdispersed count data'. Statistics in Medicine, 2013, 32, 3955-3957.	0.8	2
302	Multiple imputation for the analysis of incomplete compound variables. Canadian Journal of Statistics, 2015, 43, 240-264.	0.6	2
303	Failure time studies with intermittent observation and losses to followâ€up. Scandinavian Journal of Statistics, 2020, 47, 1035-1063.	0.9	2
304	Mitigating bias from intermittent measurement of timeâ€dependent covariates in failure time analysis. Statistics in Medicine, 2020, 39, 1833-1845.	0.8	2
305	Selection models for efficient twoâ€phase design of family studies. Statistics in Medicine, 2021, 40, 254-270.	0.8	2
306	Semiparametric recurrent event vs timeâ€ŧoâ€firstâ€event analyses in randomized trials: Estimands and model misspecification. Statistics in Medicine, 2021, 40, 3823-3842.	0.8	2

#	Article	IF	CITATIONS
307	Healthâ€related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	2
308	Statistical Models and Methods for Incomplete Data in Randomized Clinical Trials. , 2014, , 1-27.		2
309	SECOND ORDER ESTIMATING EQUATIONS FOR CLUSTERED LONGITUDINAL BINARY DATA WITH MISSING OBSERVATIONS. , 2002, , .		2
310	Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder Blood, 2007, 110, 2148-2148.	0.6	2
311	Marker-dependent observation and carry-forward of internal covariates in Cox regression. Lifetime Data Analysis, 2022, 28, 560-584.	0.4	2
312	Life history analysis with multistate models: A review and some current issues. Canadian Journal of Statistics, 2022, 50, 1270-1298.	0.6	2
313	Design issues with clinical experimental platelet transfusion studies. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 106-113.	0.2	1
314	Designing laboratory-based research studies: is it time for a change?. Transfusion, 2007, 47, 2336-2337.	0.8	1
315	Measuring and reporting the effect of an intervention: absolute measures. Transfusion, 2009, 49, 2022-2023.	0.8	1
316	Recurrent event analyses. Lifetime Data Analysis, 2010, 16, 449-450.	0.4	1
317	Inverse probability weighted estimating equations for randomized trials in transfusion medicine. Statistics in Medicine, 2013, 32, 4380-4399.	0.8	1
318	Demonstrating therapeutic equivalence of a new and established pharmaceutical or intervention: a guide for the nonâ€statistician. Transfusion, 2017, 57, 1343-1346.	0.8	1
319	Analysis of Chronic Disease Processes Based on Cohort and Registry Data. , 2017, , 305-325.		1
320	Observing Blood Management Programs through the Retrospectroscope. Anesthesiology, 2018, 129, 1060-1062.	1.3	1
321	Cost-effective Design of Growth Studies with Aggregation and Tracking. Journal of Biometrics & Biostatistics, 2018, 09, .	4.0	1
322	On estimands arising from misspecified semiparametric rateâ€based analysis of recurrent episodic conditions. Statistics in Medicine, 2019, 38, 4977-4998.	0.8	1
323	Score tests based on a finite mixture model of Markov processes under intermittent observation. Statistics in Medicine, 2019, 38, 3013-3025.	0.8	1
324	The illness-death model for family studies. Biostatistics, 2021, 22, 482-503.	0.9	1

#	Article	IF	CITATIONS
325	Response to: â€~Can biomarkers differentiate psoriatic arthritis from osteoarthritis?' by Tian <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e113-e113.	0.5	1
326	Multistate analysis from crossâ€sectional and auxiliary samples. Statistics in Medicine, 2020, 39, 387-408.	0.8	1
327	Limitations of the particle immunofiltration assay test for diagnosis of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, E250-E254.	2.0	1
328	The association between synovial fluid serine proteinase activity and response to intra-articular corticosteroid injection in psoriatic arthritis. Clinical Rheumatology, 2020, 39, 2355-2361.	1.0	1
329	Geneâ€based analysis of biâ€variate survival traits via functional regressions with applications to eye diseases. Genetic Epidemiology, 2021, 45, 455-470.	0.6	1
330	Transforming primary care for older Canadians living with frailty: mixed methods study protocol for a complex primary care intervention. BMJ Open, 2021, 11, e042911.	0.8	1
331	Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. Nature Medicine, 2022, , .	15.2	1
332	A hierarchical metaâ€analysis for settings involving multiple outcomes across multiple cohorts. Stat, 2022, 11, .	0.3	1
333	A logistic model for trend in 2 x 2 x kappa tables with applications to meta-analyses. Biometrics, 1997, 53, 352-7.	0.8	1
334	The polytomous discrimination index for predictionÂinvolving multistate processes underÂintermittent observation. Statistics in Medicine, 0, , .	0.8	1
335	Measuring and reporting the effect of an intervention: relative measures. Transfusion, 2009, 49, 9-12.	0.8	0
336	Hypothesis testing in clinical and basic science research. Transfusion, 2010, 50, 1878-1880.	0.8	0
337	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Präention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. Laboratoriums Medizin. 2011. 35. 45-54.	0.1	0
338	Marginal Methods for Multivariate Failure Times Under Event-Dependent Censoring. International Journal of Statistics and Probability, 2014, 3, .	0.1	0
339	A two-phase model for chronic disease processes under intermittent inspection. Statistics in Medicine, 2017, 36, 2016-2031.	0.8	0
340	Cohort study design for illness-death processes with disease status under intermittent observation. Biostatistics and Epidemiology, 2019, 3, 178-200.	0.4	0
341	Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019). Statistical Methods in Medical Research, 2019, 28, 1597-1598.	0.7	0
342	Research, 2019, 28, 1597-1598. Comment to the reply letter: Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019). Statistical Methods in Medical Research, 2019, 28, 1603-1603.	0.7	0

#	Article	IF	CITATIONS
343	Composite likelihood for aggregate data from clustered multistate processes under intermittent observation. Communications in Statistics - Theory and Methods, 2020, 49, 2913-2930.	0.6	0
344	Regression with incomplete multivariate surrogate responses for a latent covariate. Biostatistics and Epidemiology, 2020, 4, 247-264.	0.4	0
345	Known and Unknown Unknowns in Making Erythrocyte Transfusion Decisions. Anesthesiology, 2021, 134, 359-362.	1.3	0
346	Nested doubly robust estimating equations forÂcausal analysis with an incomplete effect modifier. Canadian Journal of Statistics, 0, , .	0.6	0
347	The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis Blood, 2004, 104, 2718-2718.	0.6	Ο
348	A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant Blood, 2005, 106, 4183-4183.	0.6	0
349	Oral iron supplementation with a micronutrient powder (Sprinkles®) provided to children with moderateâ€toâ€severe malnutrition does not increase infectious morbidity risk: a randomized, doubleâ€blind, placeboâ€controlled, nonâ€inferiority safety trial. FASEB Journal, 2010, 24, 94.7.	0.2	0
350	Statistical Considerations in the Use of Composite Endpoints in Time to Event Analyses. , 2014, , 209-226.		0
351	Event History Analysis. , 2015, , 295-304.		0
352	Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial. Blood, 2019, 134, 896-896.	0.6	0
353	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2022, 53, 151950.	1.6	0
354	Interim analyses in 2 x 2 crossover trials. Biometrics, 1995, 51, 932-45.	0.8	0
355	Design considerations in crossover trials with a single interim analysis and serial patient entry. Biometrics, 1996, 52, 732-9.	0.8	0
356	Doubly weighted estimating equations and weighted multiple imputation for causal inference with an incomplete subgroup variable. Biostatistics and Epidemiology, 0, , 1-19.	0.4	0